WO2003022302A3 - USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION - Google Patents

USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION Download PDF

Info

Publication number
WO2003022302A3
WO2003022302A3 PCT/GB2002/004158 GB0204158W WO03022302A3 WO 2003022302 A3 WO2003022302 A3 WO 2003022302A3 GB 0204158 W GB0204158 W GB 0204158W WO 03022302 A3 WO03022302 A3 WO 03022302A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcg
ovarian hyperstimulation
controlled ovarian
rates
controlled
Prior art date
Application number
PCT/GB2002/004158
Other languages
French (fr)
Other versions
WO2003022302A2 (en
Inventor
Yves Menezo
Original Assignee
Applied Research Systems
Yves Menezo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0212429-7A priority Critical patent/BR0212429A/en
Priority to MEP-392/08A priority patent/MEP39208A/en
Application filed by Applied Research Systems, Yves Menezo filed Critical Applied Research Systems
Priority to EA200400427A priority patent/EA009330B1/en
Priority to IL16078002A priority patent/IL160780A0/en
Priority to MXPA04002256A priority patent/MXPA04002256A/en
Priority to CA002457849A priority patent/CA2457849A1/en
Priority to KR10-2004-7002590A priority patent/KR20040032954A/en
Priority to JP2003526430A priority patent/JP2005501918A/en
Priority to EP02758598A priority patent/EP1425032A2/en
Priority to YU21004A priority patent/RS21004A/en
Priority to US10/489,220 priority patent/US7405197B2/en
Priority to UA2004031860A priority patent/UA82650C2/en
Publication of WO2003022302A2 publication Critical patent/WO2003022302A2/en
Publication of WO2003022302A3 publication Critical patent/WO2003022302A3/en
Priority to HRP20040087 priority patent/HRP20040087A2/en
Priority to ZA2004/00835A priority patent/ZA200400835B/en
Priority to NO20040991A priority patent/NO20040991L/en
Priority to HK05101454.2A priority patent/HK1067867A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides a protocol leading to improved embryo implantation rates and/or decreased miscarriage rates in which hCG, or a bio-analogue, is administered during the follicular phase.
PCT/GB2002/004158 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION WO2003022302A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP02758598A EP1425032A2 (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
JP2003526430A JP2005501918A (en) 2001-09-12 2002-09-12 Use of hCG in controlled superovulation stimulation
EA200400427A EA009330B1 (en) 2001-09-12 2002-09-12 Method encouraging implantation rates and/or decreased miscarriage rates and kit therefor
IL16078002A IL160780A0 (en) 2001-09-12 2002-09-12 USE OF hCG IN THE MANUFACTURE OF A MEDICAMENT
MXPA04002256A MXPA04002256A (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION.
CA002457849A CA2457849A1 (en) 2001-09-12 2002-09-12 Use of hcg in controlled ovarian hyperstimulation
MEP-392/08A MEP39208A (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
BR0212429-7A BR0212429A (en) 2001-09-12 2002-09-12 Use of hcg in controlled ovarian hyperstimulation
KR10-2004-7002590A KR20040032954A (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
US10/489,220 US7405197B2 (en) 2001-09-12 2002-09-12 Use of hCG in controlled ovarian hyperstimulation
YU21004A RS21004A (en) 2001-09-12 2002-09-12 Use of hcg in controlled ovarian hyperstimulation
UA2004031860A UA82650C2 (en) 2001-09-12 2002-12-09 Use of hcg or its analogue for controlled ovary hyperstimulation
HRP20040087 HRP20040087A2 (en) 2001-09-12 2004-01-28 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
ZA2004/00835A ZA200400835B (en) 2001-09-12 2004-02-02 Use of hcg in controlled ovarian hyperstimulation
NO20040991A NO20040991L (en) 2001-09-12 2004-03-08 Use of hCG in controlled ovarian hyperstimulation.
HK05101454.2A HK1067867A1 (en) 2001-09-12 2005-02-22 Use of hcg in controlled ovarian hyperstimulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01307757 2001-09-12
EP01307757.3 2001-09-12

Publications (2)

Publication Number Publication Date
WO2003022302A2 WO2003022302A2 (en) 2003-03-20
WO2003022302A3 true WO2003022302A3 (en) 2003-12-18

Family

ID=8182261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004158 WO2003022302A2 (en) 2001-09-12 2002-09-12 USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION

Country Status (20)

Country Link
US (1) US7405197B2 (en)
EP (1) EP1425032A2 (en)
JP (1) JP2005501918A (en)
KR (1) KR20040032954A (en)
CN (1) CN100536912C (en)
AR (1) AR036592A1 (en)
BR (1) BR0212429A (en)
CA (1) CA2457849A1 (en)
EA (1) EA009330B1 (en)
HK (1) HK1067867A1 (en)
HR (1) HRP20040087A2 (en)
IL (1) IL160780A0 (en)
ME (1) MEP39208A (en)
MX (1) MXPA04002256A (en)
NO (1) NO20040991L (en)
PL (1) PL369098A1 (en)
RS (1) RS21004A (en)
UA (1) UA82650C2 (en)
WO (1) WO2003022302A2 (en)
ZA (1) ZA200400835B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60325275D1 (en) * 2003-02-07 2009-01-22 Austria Wirtschaftsservice Gmbh USE OF HUMAN CHORION GONADOTROPIN IN THE TREATMENT OF ENDOMETRIOSIS SYMPTOMS
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20150273020A1 (en) * 2007-05-11 2015-10-01 Lori R. Bernstein Hormone Normalization Therapy and Uses Therefor
EP2243423B1 (en) * 2009-04-23 2012-05-02 Roche Diagnostics GmbH Method and device for determining recommendations for dosing agents on the basis of measurement series of at least one physiological parameter of a patient
TWI604850B (en) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
CN103619358B (en) 2011-03-31 2017-02-15 辉凌公司 Pharmaceutical preparation
US20120265129A1 (en) * 2011-04-15 2012-10-18 Neuralight Hd, Llc Methods for Chronic Pain Management and Treatment using HCG
US8680086B2 (en) 2011-04-15 2014-03-25 Neuralight Hd, Llc Methods for chronic pain management and treatment using HCG
KR20140053991A (en) 2011-07-18 2014-05-08 아츠 바이올로직스 에이/에스 Long acting luteinizing hormone (lh) compound
US10271876B2 (en) 2011-11-23 2019-04-30 Mezadata Medical Ip Holding Llc Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
US20150290292A1 (en) 2012-10-18 2015-10-15 Neuralight Hd, Llc Treatment of Depression and PTSD
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
KR20230165386A (en) 2016-07-21 2023-12-05 옵스에파 에스에이 Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CA3035055A1 (en) 2016-08-29 2018-03-08 Progena, Inc. Autologous somatic stem cell therapy, method of controllable preparation of therapeutic composition and procedure of adaptive treatment of ivf patient
RU2646578C1 (en) * 2017-02-13 2018-03-05 Федеральное государственное бюджетное военное образовательное учреждение высшего образования Военно-медицинская академия им. С.М. Кирова Министерства обороны Российской Федерации (ВМедА) Method for improving efficiency of embryo implantation in natural cycle of conception and in assisted reproductive technology (art) protocols
CN109431647B (en) * 2018-09-20 2020-10-30 华中农业大学 Processing method for simultaneous estrus and timing semen deposition of hybrid buffalo
CA3149898A1 (en) 2019-09-03 2021-03-11 Ernest Loumaye Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CA3167121A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
WO1999013081A1 (en) * 1997-09-08 1999-03-18 Akzo Nobel N.V. EXPRESSION OF GONADOTROPINS IN $i(DICTYOSTELIUM)
WO2000050066A1 (en) * 1999-02-24 2000-08-31 Novo Nordisk A/S Treatment of infertility
WO2000067778A1 (en) * 1999-05-07 2000-11-16 Applied Research Systems Ars Holding N.V. Gonadotrophins
WO2001054715A1 (en) * 2000-01-27 2001-08-02 Applied Research Systems Ars Holding N.V. Use of fsh for treating infertility

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4589402A (en) 1984-07-26 1986-05-20 Serono Laboratories, Inc. Method of in vitro fertilization
DK0994718T3 (en) 1997-06-20 2005-12-19 Akzo Nobel Nv Gonadotropin releasing hormone antagonist
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705478A (en) * 1989-02-21 1998-01-06 Washington University Covalently linked β subunits of the glycoprotein hormones as antagonists
WO1999013081A1 (en) * 1997-09-08 1999-03-18 Akzo Nobel N.V. EXPRESSION OF GONADOTROPINS IN $i(DICTYOSTELIUM)
WO2000050066A1 (en) * 1999-02-24 2000-08-31 Novo Nordisk A/S Treatment of infertility
WO2000067778A1 (en) * 1999-05-07 2000-11-16 Applied Research Systems Ars Holding N.V. Gonadotrophins
WO2001054715A1 (en) * 2000-01-27 2001-08-02 Applied Research Systems Ars Holding N.V. Use of fsh for treating infertility

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLUMENFELD Z AND RAUCH M: "Early pregnancy wastage: the role of repetitive human chorionic gonadotropin supplementation during the first 8 weeks of gestation", FERTILITY AND STERILITY, vol. 58, no. 1, 1992, pages 19 - 23, XP001077818 *
FILICORI M ET AL: "LUTEINIZING HORMONE ACTIVITY SUPPLEMENTATION ENHANCES FOLLICLE-STIMULATING HORMONE EFFICACY AND IMPROVES OVULATION INDUCTION OUTCOME", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, NEW YORK, NY, US, vol. 84, no. 8, August 1999 (1999-08-01), pages 2659 - 2663, XP001055466, ISSN: 0021-972X *
THOMPSON KA ET AL.: "Gonadotropin requirements of the developing follicle", FERTILITY AND STERILITY, vol. 63, no. 2, 1995, pages 273 - 276, XP001064790 *

Also Published As

Publication number Publication date
CN100536912C (en) 2009-09-09
MXPA04002256A (en) 2004-07-23
WO2003022302A2 (en) 2003-03-20
JP2005501918A (en) 2005-01-20
US7405197B2 (en) 2008-07-29
AR036592A1 (en) 2004-09-22
IL160780A0 (en) 2004-08-31
EA009330B1 (en) 2007-12-28
EP1425032A2 (en) 2004-06-09
CA2457849A1 (en) 2003-03-20
BR0212429A (en) 2004-10-26
US20050065069A1 (en) 2005-03-24
NO20040991L (en) 2004-03-08
UA82650C2 (en) 2008-05-12
PL369098A1 (en) 2005-04-18
CN1553808A (en) 2004-12-08
HRP20040087A2 (en) 2004-12-31
ZA200400835B (en) 2005-04-26
MEP39208A (en) 2011-02-10
RS21004A (en) 2006-12-15
KR20040032954A (en) 2004-04-17
EA200400427A1 (en) 2004-08-26
HK1067867A1 (en) 2005-04-22

Similar Documents

Publication Publication Date Title
WO2003022302A3 (en) USE OF hCG IN CONTROLLED OVARIAN HYPERSTIMULATION
HK1067865A1 (en) Use of hcg and lh in controlled ovarian hyperstimulation
EP1250954A3 (en) Microchannel device, method for producing the microchannel device and use of the same
WO2002049452A3 (en) Flavour concentrates
AU2003250188A1 (en) Stabilized, aqueous silicon dioxide dispersion
AU2002343356A1 (en) Antisense modulation of protein kinase r expression
AU2003268096A1 (en) ANTISENSE MODULATION OF Nav1.3 EXPRESSION
EP1261623A4 (en) New retinol derivatives, the method of preparations and the uses thereof
AU2003270149A1 (en) Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same
WO2002060906A8 (en) Crystal modification of olanzapine
WO2003000893A3 (en) Nucleic acids encoding g protein-coupled receptors
WO2002083608A3 (en) Methods of preparing sulfinamide and sulfoxides
AU2002328920A1 (en) Emulsifier mixture
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
AU2002342901A1 (en) Emulsifier mixture
AU2002328285A1 (en) Method for producing an essentially chlorite-free, stable, aqueous chlorine-oxygen solution, the chlorine-oxygen solution obtained by means of said method, and the use of the same
WO2002032884A3 (en) Methods for the preparation of biphenyl isoxazole sulfonamides
WO2003035722A8 (en) Methods for controlling peptide solubility, chemically modified peptides, and stable solvent systems for producing same
AUPR253901A0 (en) Emulsifier
AU2002353153A1 (en) Antisense modulation of tfap2c expression
AU2001228894A1 (en) The speech recognition(setting) of on-line-network-game
AU2002258071A1 (en) Modified polyorganosiloxanes, aqueous emulsions thereof, their production and their use
AU2002252432A1 (en) Dual loop regulator
AU2002308194A1 (en) Method for the production of 4,6-diaminopyrimido(5,4-d)pyrimidines
AU2002219699A1 (en) New retinol derivatives, the method of preparations and the uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-210/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NO NZ OM PH PT RO RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: P20040087A

Country of ref document: HR

Ref document number: 2002324179

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004/00835

Country of ref document: ZA

Ref document number: 200400835

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 278/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2457849

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047002590

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 160780

Country of ref document: IL

Ref document number: 2003526430

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/002256

Country of ref document: MX

Ref document number: 20028175735

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002758598

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200400427

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2002758598

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10489220

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002758598

Country of ref document: EP